Boston Scientific Corp.
This article was originally published in The Gray Sheet
Executive Summary
Taps Paul LaViolette to head the firm's "international sales and marketing organization" as president of Boston Scientific International, the firm announces Jan. 7. LaViolette replaces Jerry Lacey, 59, who will remain involved with the firm to a lesser degree. LaViolette comes to Boston Scientific from Bard, where he was president of the USCI division ("The Gray Sheet" March 8, 1993, In Brief). LaViolette was not one of the defendants in Bard's recent plea agreement involving the USCI business
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.